Androgen deprivation therapy (ADT) is associated with considerable adverse side effects which compromise the health and wellbeing of many men with prostate cancer. 

Exercise has been identified as a therapy to help manage ADT-related treatment toxicities. It is well known that exercise alleviates numerous side-effects experienced by men after their treatment for prostate cancer. Current exercise guidelines recommend a minimum of 150 min per week of moderate-to-vigorous aerobic exercise. However, a number of studies in colorectal and breast cancer have observed a dose-response relationship, whereby a higher intensity of exercise above the current recommendations, results in greater fitness and health. To date, the influence of high intensity exercise training in men with prostate cancer remains unknown.

Therefore, this study aims to determine the influence of 8 weeks of high intensity interval training (HIIT) in comparison to moderate-intensity continuous training (MICT) on prostate cancer (PCa) -related fatigue, quality of life, wellbeing and other markers of health in men with PCa treated with androgen deprivation therapy (ADT). Results of this study will enhance our ability to prescribe the most beneficial exercise to alleviate symptoms such as fatigue and improve the health and quality of life of men with prostate cancer treated with ADT.

You'll receive:

  • 3x free assessments of current fitness
  • 3x free assessments of cardiac health
  • 3x free assessments of body composition and bone density
  • 8 weeks (24 sessions) of free aerobic exercise training supervised by an Accredited Exercise Physiologist
  • Free parking


  • Male
  • Age +18 years
  • Diagnosis of prostate cancer (previous or current)
  • Non-smoker, or have quit smoking more than 3 months ago
  • Currently being treated with hormone therapy (ADT) or have previously been treated with ADT for more than 3 months
  • Bodyweight is less than 150 kg

Register your interest:

Contact Kirsten Adlard via email or phone: 0421 011 511.

This study has been approved by The University of Queensland Human Research Ethics Committee [Approval No. 2019000781]